Abstracts tagged "dermatomyositis"

Abstract Number: 1165 • ACR Convergence 2023
Long-term Changes in Lung Function in Melanoma Differentiation-associated Protein 5 (MDA5) Antibody Positive Dermatomyositis Patients: Experience of a Single Center Longitudinal Cohort in North America
Jenice Cheah¹, Sangmee Bae², Tiffany De Leon², Yuna Lee¹ and Christina Charles-Schoeman³, ¹University of California Los Angeles, Los Angeles, CA, ²UCLA Rheumatology, Los Angeles, CA, ³UCLA Medical Center, Santa Monica, CA
Background/Purpose: Interstitial lung disease (ILD) associated with antibodies to melanoma differentiation-associated protein 5 (MDA5 ab) in patients with dermatomyositis (DM) has been associated with a…
Abstract Number: 1946 • ACR Convergence 2023
Zetomipzomib Demonstrates Favorable Long-term Safety and Tolerability Profile Without Signs of Immunosuppression: Results from the PRESIDIO Study and Its Open-label Extension Study in Patients with Dermatomyositis and Polymyositis
Rohit Aggarwal¹, Namita Goyal², Diana Lam³, Allen Ng³, Richard Leff⁴, Kathryn Ray³, Eunmi Park³ and Noreen Henig³, ¹University of Pittsburgh, Pittsburgh, PA, ²UCI Health, Orange, CA, ³Kezar Life Sciences, South San Francisco, CA, ⁴Kezar Life Sciences, Chadds Ford, PA
Background/Purpose: Polymyositis (PM) and dermatomyositis (DM) are chronic autoimmune diseases characterized by muscle inflammation and weakness. In a collagen-induced myositis mouse model, immunoproteasome inhibition has…
Abstract Number: 0289 • ACR Convergence 2023
Markers of Endothelial Damage Are Elevated in Patients with Dermatomyositis Associated Interstitial Lung Disease and Associated with Low Paraoxonase-1 Activity
Sangmee Bae¹, Ani Shahbazian¹, Jennifer Wang², Tiffany De Leon¹, Yuna Lee¹, srinivasa Reddy³ and Christina Charles-Schoeman⁴, ¹UCLA Rheumatology, Los Angeles, CA, ²University of California Los Angeles, Los Angeles, CA, ³UCLA Department of Molecular and Medical Pharmacology, Los Angeles, CA, ⁴UCLA Medical Center, Santa Monica, CA
Background/Purpose: Damage to the vascular endothelium is implicated in the pathogenesis of idiopathic inflammatory myopathies (IIM) and its associated interstitial lung disease (ILD), with microvascular…
Abstract Number: 1167 • ACR Convergence 2023
Transcriptome Analysis of Peripheral Blood Reveals Superiority of the Triple Combination of Baricitinib, Rituximab, and Tacrolimus Therapy (BRT-Tx.) for anti-MDA5 Antibody-positive Dermatomyositis (MDA5-DM)
Yoshinobu Koyama¹, Yoshiharu Sato², Yu Nakai³ and Moe Tokunaga(Sakamoto)³, ¹Japanese Red Cross Okayama Hospital, Okayama, Japan, ²DNA Chip Research Inc, Tokyo, Japan, ³Rheumatology, Center for Autoimmune diseases, Japanese Red Cross Okayama Hospital, Okayama, Japan
Background/Purpose: MDA5-DM is characterized by high mortality due to rapid progressive ILD. We reported that in MDA-5DM, (1) RIG-1-like receptor signaling is enhanced, (2) antiviral…
Abstract Number: 1949 • ACR Convergence 2023
Relapse of Rapidly Progressive Interstitial Lung Disease in Patients with Anti-Melanoma Differentiation-Associated Gene 5 Autoantibody-Positive Dermatomyositis
Noriko Sasaki, Toshiki Ohisa, Akira Ishii, Mai Sugiyama, Yuichiro Ota, Chiho Yamada and Shinji Sato, Tokai university School of Medicine, Isehara, Japan
Background/Purpose: Autoantibodies to Melanoma Differentiation-Associated Gene 5 (MDA5) are found specifically in patients with dermatomyositis (DM). Their presence is closely associated with rapidly progressive interstitial…
Abstract Number: 0297 • ACR Convergence 2023
Characteristics of Anti-MDA-5 Associated Dermatomyositis in Southern California with a Large Hispanic Population: Case Series
Eaman Alhassan¹, Belina Yi², Jack Rodman¹ and Leanna Wise³, ¹University of Southern California, Los Angeles, CA, ²Children's Hospital Los Angeles, Los Angeles, CA, ³LAC+USC/Keck Medicine of USC, Pasadena, CA
Background/Purpose: There is little to no data about the presentation and clinical course of anti-melanoma differentiation-associated gene-5 antibody (anti-MDA-5) dermatomyositis patients in a primarily U.S.…
Abstract Number: 1175 • ACR Convergence 2023
Inclusion of All Myositis Specific Autoantibodies or Other Rashes Leads to Better Sensitivity but Lower Specificity of 2017 EULAR/ACR Myositis Classification Criteria for Dermatomyositis
Yusra Hasan¹, Katharine Ching Chung², Dana Ascherman³, Siamak Moghadam-Kia⁴, Chester V. Oddis³ and Rohit Aggarwal³, ¹CHI Health Creighton University Medical Center, Omaha, NE, ²University of Pittsburgh Medical Center, Mckeesport, PA, ³University of Pittsburgh, Pittsburgh, PA, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA
Background/Purpose: Idiopathic Inflammatory Myopathies (IIM), collectively known as myositis, are heterogeneous disorders characterized by muscle weakness and muscle inflammation. ACR/EULAR classification criterion for IIM was…
Abstract Number: 1951 • ACR Convergence 2023
Valid and Reliable Physical Function Tests in Idiopathic Inflammatory Myositis
Tanya Chandra¹, Raisa Lomanto Silva², shiri keret³, Akanksha Sharma⁴, Siamak Moghadam-Kia², Dana Ascherman⁵, Chester V. Oddis⁵ and Rohit Aggarwal⁵, ¹Georgetown University Hospital, Washington, DC, ²University of Pittsburgh Medical Center, Pittsburgh, PA, ³Bnai Zion, Atlit, Israel, ⁴UPMC Mercy Hospital, Pittsburgh, PA, ⁵University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Idiopathic inflammatory myopathies (IIM) can cause significant impairment in physical function. Sit to Stand (STS) and Timed Up and Go (TUG) are quick and…
Abstract Number: 0300 • ACR Convergence 2023
Nailfold Videocapillaroscopy in Idiopathic Inflammatory Myopathy Compared with Healthy Controls
Megan Sullivan¹, Maximiliano Diaz-Menindez², Colleen T. Ball², Benjamin Wang³ and Florentina Berianu¹, ¹Mayo Clinic Florida, Jacksonville, FL, ²Mayo Clinic Jacksonville, Jacksonville, FL, ³Mayo Clinic, Jacksonville, FL
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are a group of autoimmune disorders that cause inflammation of the muscle. This includes dermatomyositis and polymyositis. Literature has been…
Abstract Number: 1176 • ACR Convergence 2023
Brepocitinib Prevents Type-I Interferon Induced Damage in Cultured Myocytes and Endothelial Cells Indicating a Potential Role in the Treatment of Dermatomyositis
Jiri Vencovsky¹, Jolie Feldman², Lisa McConnachie² and Brendan M. Johnson², ¹Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ²Priovant Therapeutics, Durham, NC
Background/Purpose: Dermatomyositis (DM), an idiopathic inflammatory myopathy, is a chronic and often debilitating condition characterized by a hallmark skin rash (e.g., Gottron's sign and heliotrope…
Abstract Number: 1952 • ACR Convergence 2023
Anti-MDA5 Associated Dermatomyositis: Clinical Features and Outcomes in a Predominantly African-American Case Series
David Wang¹, Arezou Khosroshahi² and Prateek Gandiga², ¹Emory University School of Medicine, Atlanta, GA, ²Emory University, Atlanta, GA
Background/Purpose: Individuals with autoantibodies against melanoma differentiation-associated protein 5 (MDA-5) are reported to have a significant risk of developing rapidly progressive and fatal interstitial lung…
Abstract Number: 0301 • ACR Convergence 2023
Inflammatory Myopathies and Their Relationship with Cancer in a Colombian Cohort
Bolaños Juan D.¹, Rivera-Londoño Robert¹, Ivana Nieto-Aristizabal¹, Karol Enriquez², Santiago Zura², Alex Echeverri¹, Andrés Hormaza-Jaramillo¹ and David Aguirre-Valencia¹, ¹Fundación Valle del Lili, Cali, Colombia, ²Universidad ICESI, Cali, Colombia
Background/Purpose: Inflammatory myopathies (IM) constitute a heterogeneous group of autoimmune muscle diseases. These can occur in isolation, associated with other autoimmune disorders, or as a…
Abstract Number: 1180 • ACR Convergence 2023
Machine Learning Approach for the Prediction of anti-MDA5 Positive Dermatomyositis Mortality
Xinlei Liu¹, Fumin Qi², Wei Wei¹ and Yin Zhao¹, ¹Tianjin Medical University General Hospital, Tianjin, China, ²Tianjin Medical University, Tianjin, China
Background/Purpose: We describe a single-center clinical cohort of MDA5 positive dermatomyositis(DM) in China and apply a machine learning approach to predict the risk of mortality…
Abstract Number: 1954 • ACR Convergence 2023
Evaluation of Cancer Screening Methods in Patients Diagnosed with Inflammatory Muscle Disease at Kansas University Medical Center
Padmini Giri¹, Amrita Bath² and Pooja Bhadbhade², ¹University of Kansas Medical Center, Overland Park, KS, ²University of Kansas Medical Center, Kansas City, MO
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are characterized by muscle weakness and inflammation. There is an increased risk of developing cancer in patients (pts) with IIM…
Abstract Number: 0307 • ACR Convergence 2023
Long-term Prognosis and Recurrence in anti-MDA-5 Antibody-positive Dermatomyositis
Jun Nakamura¹, Takao Nagashima² and Kojiro Sato², ¹Jichi Medical University, Shimotsuke, Japan, ²Jichi Medical University, Tochigi, Japan
Background/Purpose: Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (DM) is frequently complicated by rapidly progressive interstitial lung disease (ILD) and is life-threatening especially in the…

« Previous Page
1
…
4
5
6
7
8
…
24
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].